Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01579422 · ClinicalTrials.gov registry record · Phase 1
Social Cognitive Training for Psychosis: Treatment Development
A Phase 1 study of Schizophrenia and Psychosis, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
- 1
- Study location
NCT01579422 is a Phase 1 study of Schizophrenia and Psychosis that has completed, run by Yale University. The registered enrollment target is 77 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01579422, a Phase 1 study of Schizophrenia and Psychosis, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of this proposal is to develop, refine, manualize and assess the feasibility and preliminary efficacy of a brief, narrowly-focused social cognitive intervention for individuals with psychosis. The intervention will focus on helping individuals interpret social situations, specifically the intentions and feelings of others. Study methods include preliminary treatment and manual development based on series of uncontrolled cases, manual refinement, and a small feasibility/efficacy trial of the newly developed intervention.
Conditions Studied
Interventions
- BEHAVIORAL social cognitive training
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2012-05 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01579422
The ClinicalTrials.gov registry entry for NCT01579422 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (65% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which social cognitive training is the first listed.
NCT01579422 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT01579422 about?
NCT01579422 is a clinical study titled "Social Cognitive Training for Psychosis: Treatment Development". The primary aim of this proposal is to develop, refine, manualize and assess the feasibility and preliminary efficacy of a brief, narrowly-focused social cognitive intervention for individuals with psychosis. The intervention will focus on helping individuals interpret social situations, specificall...
What is the current status of trial NCT01579422?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2012-05. Estimated completion is 2015-12.
What conditions does trial NCT01579422 study?
This clinical trial studies the following conditions: Schizophrenia, Psychosis.
What interventions are being tested in trial NCT01579422?
The interventions under investigation include: social cognitive training (BEHAVIORAL).
Who is sponsoring clinical trial NCT01579422?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01579422 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.